90888-62-3

Usage

Uses

Used in Pharmaceutical Industry:
(1H-Indol-2-ylmethyl)methylamine is utilized as a building block for the synthesis of pharmaceuticals due to its ability to contribute to the development of indole-based drugs. Its presence in these compounds can enhance their efficacy and pharmacological properties, making it an essential component in the creation of novel medications.
Used in Agrochemical Industry:
In the agrochemical sector, (1H-Indol-2-ylmethyl)methylamine serves as a key intermediate in the production of various agrochemicals. Its incorporation can lead to the development of more effective and targeted agrochemicals, contributing to improved agricultural practices and crop protection.
Used in Fine Chemicals Industry:
(1H-Indol-2-ylmethyl)methylamine is also used as an intermediate in the synthesis of fine chemicals. Its versatility allows for its use in a wide range of applications, from the creation of specialty chemicals to the development of complex organic compounds for research and commercial purposes.
Used in Medicinal Chemistry Research:
(1H-Indol-2-ylmethyl)methylamine is employed as a valuable tool in medicinal chemistry research. Its ability to modulate the activity of biological targets makes it instrumental in the discovery and development of new drugs, as well as in understanding the mechanisms of action of existing pharmaceuticals.

Upstream product

• 1477-50-5 Indole-2-carboxylic acid 
• 58881-45-1 Indole-2-carbonyl chloride 
• 19005-93-7 1H-indol-2-ylcarboxaldehyde 
• 74-89-5 methylamine 
• 69808-71-5 1H-indole-2-carboxylic acid methylamide 

Relevant academic research and scientific papers

Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity

CrtN has been identified as an attractive and druggable target for treating pigmented Staphylococcus aureus infections. More than 100 new compounds were synthesized, which target the overwhelming the defects of the CrtN inhibitor 1. Analogues 23a and 23b demonstrated a significant activity against pigmented S. aureus Newman and 13 MRSA strains (IC50 = 0.02-10.5 nM), along with lower hERG inhibition (IC50 > 30 μM, ～10-fold decrease in comparison with 1). Furthermore, 23a and 23b were confirmed to reduce the staphylococcal load in the kidney and heart in a mouse model with normal treatment deeper than pretreatment ones, comparable even with vancomycin and linezolid. Remarkably, 23a could strongly block the pigment biosynthesis of these nine multidrug-resistant MRSA strains, including excellent activity against LRSA strains and VISA strains in vivo, and all of which demonstrated that 23a has a huge potential against intractable MRSA, VISA, and LRSA issues as a therapeutic drug.

Synthesis of heteroarylogous 1H-indole-3-carboxamidines via a three-component interrupted Ugi reaction

A novel one-pot multicomponent synthesis of heteroarylogous 1H-indole-3-carboxamidines starting from readily available N-alkyl-N-(1H-indol-2-ylmethyl)amines, isocyanides, and carbonyl compounds is reported. The strategy exploits the ability of the indole nucleus to interrupt the classical Ugi reaction, by intercepting the nascent nitrilium ion.

FAB I INHIBITORS

Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.